122 related articles for article (PubMed ID: 11830347)
1. Persistence of YMDD variants after withdrawal of Lamivudine.
van der Eijk AA; Niesters HG; Pas SD; de Man RA
J Hepatol; 2002 Feb; 36(2):304-5. PubMed ID: 11830347
[No Abstract] [Full Text] [Related]
2. Hepatitis B viral genotypes and lamivudine resistance.
Kao JH; Liu CJ; Chen DS
J Hepatol; 2002 Feb; 36(2):303-4. PubMed ID: 11830346
[No Abstract] [Full Text] [Related]
3. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
[TBL] [Abstract][Full Text] [Related]
4. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
5. [Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
Yang DH; Xie YJ; Liang WF; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):496-7. PubMed ID: 15329216
[No Abstract] [Full Text] [Related]
6. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea.
Paik YH; Chung HY; Ryu WS; Lee KS; Lee JS; Kim JH; Lee CK; Chon CY; Moon YM; Han KH
J Hepatol; 2001 Jul; 35(1):92-8. PubMed ID: 11495048
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns.
Honkoop P; Niesters HG; de Man RA; Osterhaus AD; Schalm SW
J Hepatol; 1997 Jun; 26(6):1393-5. PubMed ID: 9210628
[TBL] [Abstract][Full Text] [Related]
8. Lamivudine resistant occult HBV: implications for public health?
Bowden S; Bartholomeusz A; Locarnini S
J Hepatol; 2003 Apr; 38(4):526-8. PubMed ID: 12663248
[No Abstract] [Full Text] [Related]
9. Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains.
Kuwahara R; Kumashiro R; Inoue H; Tanabe R; Tanaka E; Hino T; Ide T; Koga Y; Sata M
Dig Dis Sci; 2004 Feb; 49(2):300-3. PubMed ID: 15104374
[No Abstract] [Full Text] [Related]
10. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
Mori K; Minami M; Kirishima T; Kunimoto K; Okita M; Nakayama M; Makiyama A; Yamaoka J; Nakajima T; Yasui K; Itoh Y; Okanoue T
Intervirology; 2006; 49(5):274-80. PubMed ID: 16714856
[TBL] [Abstract][Full Text] [Related]
11. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
12. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.
Zöllner B; Sterneck M; Wursthorn K; Petersen J; Schröter M; Laufs R; Feucht HH
J Clin Microbiol; 2005 May; 43(5):2503-5. PubMed ID: 15872296
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine therapy for Japanese patients with cirrhosis B.
Okanoue T; Mori K; Kirishima T; Kunimoto K; Yasui K; Itoh Y; Minami M
Intervirology; 2003; 46(6):394-9. PubMed ID: 14688458
[TBL] [Abstract][Full Text] [Related]
15. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients.
Fontaine H; Thiers V; Chrétien Y; Zylberberg H; Poupon RE; Bréchot C; Legendre C; Kreis H; Pol S
Transplantation; 2000 May; 69(10):2090-4. PubMed ID: 10852602
[TBL] [Abstract][Full Text] [Related]
16. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
Lin CL; Tsai SL; Lee TH; Chien RN; Liao SK; Liaw YF
Gut; 2005 Jan; 54(1):152-61. PubMed ID: 15591521
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
[TBL] [Abstract][Full Text] [Related]
18. HBV resistant to lamivudine: experimental and clinical studies.
Zhou DY; Cao YJ; Lin LY; Wang H; Huang JS
Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):519-22. PubMed ID: 14607678
[TBL] [Abstract][Full Text] [Related]
19. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine.
Yang DH; Liang WF; Xie YJ; Zhao NF; Fan J
Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):232-7. PubMed ID: 14612274
[TBL] [Abstract][Full Text] [Related]
20. [Lamivudine resistance impedes hepatitis B therapy].
Eggers HJ
Fortschr Med; 1997 Apr; 115(12):5. PubMed ID: 9235306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
